Advanced search
Publication Cover
Cancer Investigation Volume 23, 2005 - Issue 1
Submit an article Journal homepage
69
Views
31
CrossRef citations to date
0
Altmetric
Original Article

Oxaliplatin for Pretreated Patients with Advanced or Metastatic Pancreatic Cancer: A Multicenter Phase II Study

Nikolaos Androulakis Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion, Crete, 711 10, Greece
,
Konstantinos Syrigos Medical Oncology Unit 3, Department of Internal Medicine, Hospital of Pulmonary Diseases, Athens, Greece
,
Aristidis Polyzos Medical Oncology Unit, “Laiko” Hospital of Athens, Athens, Greece
,
Gerasimos Aravantinos 3rd Department of Medical Oncology, Agii Anargyri Anticancer Hospital, Athens, Greece
,
George P. Stathopoulos Medical Oncology Unit, “E. Dynan” General Hospital, Athens, Greece
,
Nikolaos Ziras Department of Medical Oncology, “METAXA” Anticancer Hospital, Athens, Greece
,
Konstantinos Mallas Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion, Crete, 711 10, Greece
,
Lambros Vamvakas Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion, Crete, 711 10, Greece
,
Vassilis Georgoulias Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion, Crete, 711 10, Greece; Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion, Crete, 711 10, Greece
, Ph.D. , M.D. &
for the Hellenic Oncology Research Group (HORG) Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion, Crete, 711 10, Greece; Medical Oncology Unit 3, Department of Internal Medicine, Hospital of Pulmonary Diseases, Athens, Greece; Medical Oncology Unit, “Laiko” Hospital of Athens, Athens, Greece; 3rd Department of Medical Oncology, Agii Anargyri Anticancer Hospital, Athens, Greece; Medical Oncology Unit, “E. Dynan” General Hospital, Athens, Greece; Department of Medical Oncology, “METAXA” Anticancer Hospital, Athens, Greece
 show all
Pages 9-12 | Published online: 11 Jun 2009
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

A phase II study was designed to evaluate the efficacy and safety of oxaliplatin as second-line treatment in patients with locally advanced or metastatic pancreatic cancer. Eighteen patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy, received oxaliplatin 130 mg/m2 i.v. every 21 days. Patients were treated until tumor progression or unacceptable toxicity. No objective response was observed among the 18 treated patients. Three (16.7%) patients had stable disease for > 2 months. A clinical benefit response was observed in five (27.7%) patients. Toxicity was mild. Oxaliplatin as second-line treatment for patients with unresectable pancreatic cancer is well tolerated and associated with improvement of tumor-related symptoms despite its failure to induce objective responses. LOHP merits further investigation in combination with other drugs as palliative treatment of pretreated patients with advanced pancreatic cancer.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,193.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.